A novel insulin formulation with a more rapid onset of action.
about
Role of insulin in the type 2 diabetes therapy: past, present and futureIncreasing local blood flow by warming the application site: beneficial effects on postprandial glycemic excursionsA review of a family of ultra-rapid-acting insulins: formulation developmentAddressing unmet medical needs in type 2 diabetes: a narrative review of drugs under developmentClosed-loop insulin delivery for treatment of type 1 diabetesPharmacokinetic Model of the Transport of Fast-Acting Insulin From the Subcutaneous and Intradermal Spaces to Blood[Fast-acting insulin - new developments towards more flexibility for the patient].AP@home: a novel European approach to bring the artificial pancreas home.Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes.Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device.Update on insulin therapy for type 2 diabetesNeedle-free jet injection of rapid-acting insulin improves early postprandial glucose control in patients with diabetes.Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations.New insulins and insulin therapy.Closed-loop insulin delivery: from bench to clinical practice.Ultrafast-acting insulins: state of the artInsulin therapies: Current and future trends at dawn.Moving toward the ideal insulin for insulin pumps.Confusion Regarding Duration of Insulin Action: A Potential Source for Major Insulin Dose Errors by Bolus Calculators.Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin.Ultra-rapid absorption of recombinant human insulin induced by zinc chelation and surface charge masking.Subcutaneous injection versus subcutaneous infusion of insulin: are the rates of absorption truly the same?Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes.U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?
P2860
Q22241148-2B9B6472-6F01-4412-9544-A3BB7FD2F64AQ26823106-3F649477-5E45-421B-A0CF-FCE3263B66E4Q26823197-74FF6FE6-EDC5-408B-8E8C-B5415A470012Q26830274-9B75C458-EBC7-418B-8598-162373BFB213Q27008127-E07FC3F8-72B6-487E-8227-24521FF9A053Q30300391-27E89AC0-6058-4892-97A7-8F8F992006FCQ30313628-47DF167A-D563-4F95-871B-A8244C3BDF7BQ30424293-84EFBF53-B794-44D2-B95F-AE5E34F6E02DQ33556716-0CCDC0F7-04A4-4CEF-AA22-D59558D4AAC1Q35337607-62233B64-EF3C-40DD-98B6-FAE0508F4CC7Q36229266-1FD4063D-631D-4E1E-8824-3B515A210AF0Q36609298-AF1FDBB9-A6F4-4F9B-9462-8B73AEBE0D65Q37217511-35770EED-DB32-49F5-BDA9-FB952E50D873Q37278273-FAC912E8-0237-427D-9EF8-C309928230A9Q37716042-5956F8E9-411F-4434-A752-7F331AF442D8Q37842705-EDB71BD4-F957-4A1A-A2E9-EEEB685E6923Q37846089-32E67B79-A1E9-4AC5-A0FC-2018F7C77808Q38037727-476F6F54-FE03-49C0-B760-BE8D3AFC5833Q38089594-E57C0513-31BF-47F6-9A7D-63BA16B146D8Q38631154-33BAA73B-50CB-4BE3-8819-071C2C7720F3Q41873997-7C21C4B8-51E7-4B6B-8A9E-91C5FD7FEF22Q41982648-E269D540-D51F-472C-9B26-91C4CD971DC6Q42268809-504E9C35-0A8A-49F8-8A0D-3D59A4130EBCQ42959127-8A5144EE-CCA3-47BD-95F3-BE3104FA6A12Q46268392-7CFA2FD8-6198-4542-B3AB-DE90FD31A1ADQ51367050-8F3C3AE6-926B-4AED-A766-63D5E35AD0E1Q52590826-3CBB83CA-F974-4549-9736-5124A65B7DEB
P2860
A novel insulin formulation with a more rapid onset of action.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A novel insulin formulation with a more rapid onset of action.
@en
type
label
A novel insulin formulation with a more rapid onset of action.
@en
prefLabel
A novel insulin formulation with a more rapid onset of action.
@en
P2093
P1433
P1476
A novel insulin formulation with a more rapid onset of action
@en
P2093
A Pfützner
L Heinemann
P2860
P2888
P304
P356
10.1007/S00125-008-1095-8
P577
2008-07-19T00:00:00Z